AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22863299 — intervention group
Group type: EXPERIMENTAL
Intervention: Case finding and collaborative care
Number of subjects: 162
Study 22863299 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 162
Study 19918186 — intervention group
Group type: EXPERIMENTAL
Intervention: 720 ms duration Italian word presented 80 times; signals from 16 electrodes were averaged and displayed as traces and maps.
Number of subjects: 36
Study 19918186 — intervention group
Group type: COMPARATOR
Intervention: 300 Hz tone of the same duration (720 ms); signals from 16 electrodes were averaged and displayed as traces and maps.
Number of subjects: 36
Study 17989152 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized salbutamol (5 mg)
Number of subjects: 24
Study 17989152 — intervention group
Group type: COMPARATOR
Intervention: Nebulization of ipratropium bromide (0.5 mg)
Number of subjects: 24
Study 15309429 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran oil (RBO) with low gamma-oryzanol (0.05 g/d)
Number of subjects: 30
Study 15309429 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran oil (RBO) with high gamma-oryzanol (0.8 g/d)
Number of subjects: 30
Study 15309429 — intervention group
Group type: COMPARATOR
Intervention: Peanut oil (PNO) during run-in period
Number of subjects: 30
Study 11873027 — intervention group
Group type: EXPERIMENTAL
Intervention: Paresthesia technique using insulated or noninsulated needle connected to a peripheral nerve stimulator (power off)
Number of subjects: 30
Study 11873027 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulator turned on at the point of paresthesia
Number of subjects: 30
Study 10073603 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased IL-13 mRNA expression in CD4+ and CD8+ T cells during nephrotic relapse compared to remission, normal, and patient controls (P < 0.008).
Number of subjects: 55
Study 10073603 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased cytoplasmic IL-13 expression in phorbol myristate acetate/ionomycin-activated CD3+ cells from patients with nephrotic relapse (6.66+/‐3.39%) compared to remission (2.59+/‐1.35%) (P < 0.0001).
Number of subjects: 55
Study 10073603 — intervention group
Group type: EXPERIMENTAL
Intervention: No significant difference in CD4+ or CD8+ IL-2, interferon-gamma, and IL-4 mRNA expression.
Number of subjects: 55
Study 7577887 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 25 ng/min per kg ideal body weight for 90 min after fasting for 12, 36, and 72 hours
Number of subjects: 9
Study 7577887 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion
Number of subjects: 9
Study 2040935 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam-arginine plus ampicillin
Number of subjects: 30
Study 2040935 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus ampicillin
Number of subjects: 30
Study 2040935 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 7259326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion at a dose of 6‐10 ng/kg/min for 72 hours
Number of subjects: 12
Study 7259326 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion
Number of subjects: 12
Study 7259326 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 12
Study 31089768 — intervention group
Group type: EXPERIMENTAL
Intervention: PZQ + KTZ (20 mg/kg PZQ + 200 mg ketoconazole)
Number of subjects: 0
Study 31089768 — intervention group
Group type: COMPARATOR
Intervention: PZQ alone (20 mg/kg)
Number of subjects: 0
Study 28368549 — intervention group
Group type: EXPERIMENTAL
Intervention: Take a Stand! intervention
Number of subjects: 317
Study 28368549 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual behavior)
Number of subjects: 317
Study 26907933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost Unit Dose Preservative Free (BUDPF)
Number of subjects: 0
Study 26907933 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost Unit Dose Preservative Free (LUDPF)
Number of subjects: 0
Study 26907933 — intervention group
Group type: EXPERIMENTAL
Intervention: BUDPF
Number of subjects: 0
Study 26907933 — intervention group
Group type: EXPERIMENTAL
Intervention: LUDPF
Number of subjects: 0
Study 24067348 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 410
Study 24067348 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 410
Study 22655047 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Integrated Care (MIC)
Number of subjects: 10
Study 22655047 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 10
Study 19101664 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-training program
Number of subjects: 22
Study 19101664 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 16645458 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 0.0005% epinephrine
Number of subjects: 80
Study 16645458 — intervention group
Group type: COMPARATOR
Intervention: Preservative‐free saline
Number of subjects: 80
Study 12499320 — intervention group
Group type: COMPARATOR
Intervention: 4 g EPA+DHA (4:0)
Number of subjects: 31
Study 12499320 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g EPA+DHA plus 1 g GLA (4:1)
Number of subjects: 31
Study 12499320 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g GLA (4:2)
Number of subjects: 31
Study 12499320 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g GLA (4:4)
Number of subjects: 31
Study 10820352 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal color Doppler ultrasound (TV‐CDU)
Number of subjects: 88
Study 10820352 — intervention group
Group type: COMPARATOR
Intervention: Serum SCC levels
Number of subjects: 88
Study 8869688 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg/day for 3 days)
Number of subjects: 109
Study 8869688 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (50 mg/day for 3 days)
Number of subjects: 109
Study 1531552 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 256
Study 1531552 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 256
Study 1531552 — intervention group
Group type: COMPARATOR
Intervention: Continued treatment by the general practitioner
Number of subjects: 256
Study 1531552 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (detuned ultrasound and detuned short‐wave diathermy)
Number of subjects: 256
Study 6360749 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT)
Number of subjects: 0
Study 6360749 — intervention group
Group type: COMPARATOR
Intervention: Acetysalicylic acid (ASA)
Number of subjects: 0
Study 31074823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab therapy for 8 weeks or more
Number of subjects: 401
Study 31074823 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model using week-6 albumin to CRP ratio
Number of subjects: 401
Study 31074823 — intervention group
Group type: EXPERIMENTAL
Intervention: Week-8 model
Number of subjects: 401
Study 28658582 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (10 mg.kg‐1 body mass of sodium nitrate)
Number of subjects: 11
Study 28658582 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation
Number of subjects: 11
Study 25239019 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex multidisciplinary intervention (GNS-led staff education, facility benchmarking, GNS resident review, multidisciplinary discussions) for 9 months
Number of subjects: 1998
Study 25239019 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex multidisciplinary intervention
Number of subjects: 1998
Study 25239019 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1998
Study 23388533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon (in tablets) administered under standard regimen to frequently ill children (FIC)
Number of subjects: 250
Study 23388533 — intervention group
Group type: COMPARATOR
Intervention: Control group of frequently ill children (FIC)
Number of subjects: 250
Study 21756323 — intervention group
Group type: COMPARATOR
Intervention: Metformin 850 mg bid (n = 42)
Number of subjects: 121
Study 21756323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg bid (n = 40)
Number of subjects: 121
Study 21756323 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pioglitazone 30 mg and metformin 1.7 g (n = 39)
Number of subjects: 121
Study 19371961 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Encoded Signal Processing And Recognition (TESPAR) technique combined with multi-layer perceptrons for DOA estimation.
Number of subjects: 0
Study 19371961 — intervention group
Group type: EXPERIMENTAL
Intervention: TESPAR technique
Number of subjects: 0
Study 16828598 — intervention group
Group type: EXPERIMENTAL
Intervention: SC plus nesiritide 0.005 microg/kg/min
Number of subjects: 138
Study 16828598 — intervention group
Group type: EXPERIMENTAL
Intervention: SC plus nesiritide 0.010 microg/kg/min
Number of subjects: 138
Study 16828598 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 138
Study 14679315 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based milk and yoghurt (treatment)
Number of subjects: 26
Study 14679315 — intervention group
Group type: COMPARATOR
Intervention: Equivalent dairy products (control)
Number of subjects: 26
Study 11532479 — intervention group
Group type: EXPERIMENTAL
Intervention: IN/hMG
Number of subjects: 379
Study 11532479 — intervention group
Group type: COMPARATOR
Intervention: SC/FSH
Number of subjects: 379
Study 11532479 — intervention group
Group type: EXPERIMENTAL
Intervention: SC/hMG
Number of subjects: 379
Study 11532479 — intervention group
Group type: EXPERIMENTAL
Intervention: IN/FSH
Number of subjects: 379
Study 9760639 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific + Variable
Number of subjects: 75
Study 9760639 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific + Varplus
Number of subjects: 75
Study 9760639 — intervention group
Group type: COMPARATOR
Intervention: Specific
Number of subjects: 75
Study 8138776 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Measurement Questionnaire (HMQ)
Number of subjects: 430
Study 8138776 — intervention group
Group type: COMPARATOR
Intervention: General Health Questionnaire (GHQ)
Number of subjects: 430
Study 8138776 — intervention group
Group type: COMPARATOR
Intervention: Nottingham Health Profile (NHP)
Number of subjects: 430
Study 2899663 — intervention group
Group type: EXPERIMENTAL
Intervention: Feverfew (one capsule of dried feverfew leaves a day for four months)
Number of subjects: 72
Study 2899663 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for four months)
Number of subjects: 72
Study 30575345 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy (Group 1)
Number of subjects: 32
Study 30575345 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (Group 2)
Number of subjects: 32
Study 27470681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA) 1 g loading dose followed by 1 g over 8 hours
Number of subjects: 66
Study 27470681 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 0.9% normal saline (placebo)
Number of subjects: 66
Study 27470681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA)
Number of subjects: 66
Study 25694536 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat pulmonary vein isolation (PVI)
Number of subjects: 77
Study 25694536 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI with an additional left atrial anterior line
Number of subjects: 77
Study 25694536 — intervention group
Group type: COMPARATOR
Intervention: PVI
Number of subjects: 77
Study 25694536 — intervention group
Group type: COMPARATOR
Intervention: PVI + anterior line
Number of subjects: 77
Study 23564052 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 100
Study 23564052 — intervention group
Group type: COMPARATOR
Intervention: Conventional Myomectomy (MYG)
Number of subjects: 100
Study 20681234 — intervention group
Group type: EXPERIMENTAL
Intervention: Level Walking (LW)
Number of subjects: 10
Study 20681234 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill Walking (DW)
Number of subjects: 10
Study 20681234 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LW and DW
Number of subjects: 10
Study 18194526 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded task with action planning
Number of subjects: 340
Study 18194526 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive communication
Number of subjects: 340
Study 18194526 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 340
Study 17187695 — intervention group
Group type: EXPERIMENTAL
Intervention: CCE booklet
Number of subjects: 308
Study 17187695 — intervention group
Group type: COMPARATOR
Intervention: AZ booklet
Number of subjects: 308
Study 15125484 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, p.o.)
Number of subjects: 24
Study 11151233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (MMC) 0.2 mg/ml for 2 minutes
Number of subjects: 17
Study 11151233 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MMC)
Number of subjects: 17
Study 11151233 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (MMC)
Number of subjects: 17
Study 9074367 — intervention group
Group type: EXPERIMENTAL
Intervention: High vacuum drainage system
Number of subjects: 141
Study 9074367 — intervention group
Group type: COMPARATOR
Intervention: Low vacuum drainage system
Number of subjects: 141
Study 8020029 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated atrial fibrillation (AF)
Number of subjects: 0
Study 8020029 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification for thromboembolism
Number of subjects: 0
Study 8020029 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent onset AF
Number of subjects: 0
Study 8020029 — intervention group
Group type: EXPERIMENTAL
Intervention: Underlying heart disease
Number of subjects: 0
Study 3623744 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone (DDS) 100 mg orally in dogs
Number of subjects: 10
Study 3623744 — intervention group
Group type: COMPARATOR
Intervention: Dapsone (DDS) 100 mg intravenously in dogs
Number of subjects: 10
Study 3623744 — intervention group
Group type: COMPARATOR
Intervention: Dapsone (DDS) 50 mg intravenously in healthy volunteers
Number of subjects: 10
Study 3623744 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone (DDS) 50 mg orally in healthy volunteers
Number of subjects: 10
Study 30100314 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural insoles with corrective elements for equinovarus foot
Number of subjects: 20
Study 30100314 — intervention group
Group type: COMPARATOR
Intervention: Placebo insoles with no corrective elements
Number of subjects: 20
Study 27598379 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) technique, performed daily over eight weeks.
Number of subjects: 40
Study 27598379 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 40
Study 24119823 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of methylphenidate (MPH)
Number of subjects: 30
Study 24119823 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of levodopa (LEV)
Number of subjects: 30
Study 24119823 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 30
Study 22669008 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone elastomer (SE) contact lenses
Number of subjects: 57
Study 22669008 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas permeable (RGP) contact lenses
Number of subjects: 57
Study 19596580 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemicellulose dressing
Number of subjects: 28
Study 19596580 — intervention group
Group type: COMPARATOR
Intervention: Rayon dressing
Number of subjects: 28
Study 17846935 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (PcV) for five days
Number of subjects: 179
Study 17846935 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (PcV)
Number of subjects: 179
Study 17846935 — intervention group
Group type: COMPARATOR
Intervention: No primary antibiotic treatment
Number of subjects: 179
Study 15378235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical radiofrequency energy (RF) tissue micro-remodeling
Number of subjects: 41
Study 12586130 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/day
Number of subjects: 202
Study 12586130 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/day and warfarin (INR 2.0-2.5)
Number of subjects: 202
Study 12586130 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (INR 2.8-4.2)
Number of subjects: 202
Study 12586130 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin groups combined (n=129)
Number of subjects: 202
Study 9824878 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced verbal instruction
Number of subjects: 32
Study 9824878 — intervention group
Group type: COMPARATOR
Intervention: Monetary reinforcement (high vs. low)
Number of subjects: 32
Study 9824878 — intervention group
Group type: COMPARATOR
Intervention: Standard instructions (control group)
Number of subjects: 32
Study 7916881 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhine fish consumption
Number of subjects: 149
Study 7916881 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Rhine fish)
Number of subjects: 149
Study 2086257 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanol
Number of subjects: 20
Study 2086257 — intervention group
Group type: COMPARATOR
Intervention: Nitinol
Number of subjects: 20
Study 907396 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 174
Study 907396 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal vagotomy with antrectomy (TV + A)
Number of subjects: 174
Study 907396 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective gastric vagotomy with Finney pyloroplasty (SGV + P)
Number of subjects: 174
Study 30980315 — intervention group
Group type: EXPERIMENTAL
Intervention: Subterranean pulmonary rehabilitation (Group I)
Number of subjects: 42
Study 30980315 — intervention group
Group type: COMPARATOR
Intervention: Surface pulmonary rehabilitation (Group II)
Number of subjects: 42
Study 28846767 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 µg/d transdermal 17β‐estradiol (t‐E2)
Number of subjects: 670
Study 28846767 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg/d oral conjugated equine estrogens (o‐CEE)
Number of subjects: 670
Study 28846767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 670
Study 25962988 — intervention group
Group type: EXPERIMENTAL
Intervention: C-arm computed tomography (CT)
Number of subjects: 50
Study 25962988 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 50
Study 23537605 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Treatment Orders (CTOs)
Number of subjects: 333
Study 23537605 — intervention group
Group type: COMPARATOR
Intervention: Section 17 leave
Number of subjects: 333
Study 21784215 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group 1 (EG1) - taught using pictograms in the clinic
Number of subjects: 225
Study 21784215 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group 2 (EG2) - taught using pictograms in the clinic and given pictograms to take home
Number of subjects: 225
Study 21784215 — intervention group
Group type: COMPARATOR
Intervention: Control group - given verbal instruction only
Number of subjects: 225
Study 20205551 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroPage system
Number of subjects: 12
Study 16197583 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g isomalt daily
Number of subjects: 19
Study 16197583 — intervention group
Group type: COMPARATOR
Intervention: 30 g sucrose daily (Control)
Number of subjects: 19
Study 14612516 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 positive individuals
Number of subjects: 85
Study 9987085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial norepinephrine (30 to 240 pmol/min)
Number of subjects: 2
Study 9987085 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (5 pmol/min)
Number of subjects: 2
Study 9987085 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective endothelin A (ETA) receptor antagonist BQ-123 (3 mg/hr)
Number of subjects: 2
Study 9987085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed endothelin-converting enzyme and neutral endopeptidase inhibitor phosphoramidon (30 nmol/min)
Number of subjects: 2
Study 9987085 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective neutral endopeptidase inhibitor thiorphan (30 nmol/min)
Number of subjects: 2
Study 7503196 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% clindamycin vaginal cream
Number of subjects: 745
Study 7503196 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 745
Study 2106274 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 0.4 mg
Number of subjects: 150
Study 2106274 — intervention group
Group type: COMPARATOR
Intervention: Naloxone 0.05 mg
Number of subjects: 150
Study 2106274 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine 20 mg
Number of subjects: 150
Study 6444445 — intervention group
Group type: EXPERIMENTAL
Intervention: TSPA
Number of subjects: 1613
Study 6444445 — intervention group
Group type: EXPERIMENTAL
Intervention: FdUrd
Number of subjects: 1613
Study 6444445 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 1613
Study 6444445 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1613
Study 29642094 — intervention group
Group type: EXPERIMENTAL
Intervention: SPS-MC (sodium picosulphate/magnesium citrate preparation)
Number of subjects: 341
Study 29642094 — intervention group
Group type: COMPARATOR
Intervention: PEG-Asc+B (2-l ascorbic-acid-enriched polyethylene glycol solution plus bisacodyl pretreatment)
Number of subjects: 341
Study 28514963 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICE intervention (multi-contact, extended counseling intervention)
Number of subjects: 304